title: PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.
abstract: The programmed death-1 (PD-1) molecule is mainly expressed on functionally "exhausted" CD8(+) T cells, dampening the host antitumor immune response. We evaluated the ratio between effective and regulatory T cells (Tregs) and PD-1 expression as a prognostic factor for operable breast cancer patients. A series of 218 newly diagnosed invasive breast cancer patients who had undergone primary surgery at Ruijin Hospital were identified. The influence of CD8(+) cytotoxic T lymphocytes, FOXP3(+) (Treg cell marker), and PD-1(+) immune cell counts on prognosis was analyzed utilizing immunohistochemistry. Both PD-1(+) immune cells and FOXP3(+) Tregs counts were significantly associated with unfavorable prognostic factors. In bivariate, but not multivariate analysis, high tumor infiltrating PD-1(+) cell counts correlated with significantly shorter patient survival. Our results suggest a prognostic value of the PD-1(+) immune cell population in such breast cancer patients. Targeting the PD-1 pathway may be a feasible approach to treating patients with breast cancer.
authors: Shanghai Ruijin Hospital, Comprehensive Breast Health Center, Shanghai, 200025, China.
authors: Shenyou
authors: S
authors: Sun
authors: Xiaochun
authors: X
authors: Fei
authors: Yan
authors: Y
authors: Mao
authors: Xiumin
authors: X
authors: Wang
authors: David H
authors: DH
authors: Garfield
authors: Ou
authors: O
authors: Huang
authors: Jinglong
authors: J
authors: Wang
authors: Fei
authors: F
authors: Yuan
authors: Long
authors: L
authors: Sun
authors: Qixiang
authors: Q
authors: Yu
authors: Xiaolong
authors: X
authors: Jin
authors: Jianhua
authors: J
authors: Wang
authors: Kunwei
authors: K
authors: Shen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D017209:Apoptosis / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018275:Carcinoma, Lobular / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D051858:Forkhead Transcription Factors / Q000032:analysis; D006801:Humans; D053208:Kaplan-Meier Estimate; D018655:Lymphocyte Count; D016246:Lymphocytes, Tumor-Infiltrating / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D008408:Mastectomy; D008875:Middle Aged; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis*; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000737:chemistry / Q000276:immunology* / Q000473:pathology
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor